Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | THRB | P10828 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | ACHE | P22303 | 1/20 | 0.76 |
| ▸ | APEX1 | P27695 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.76 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058414 | 0.88 | HSD17B10 (0.89) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL28562897 | 0.88 | HSD17B10 (0.61) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL51065 | 0.86 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL2128472 | 0.86 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL1981737 | 0.86 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL7924 | 0.86 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL4611014 | 0.86 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL25257437 | 0.85 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7914749 | 0.85 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL4898905 | 0.85 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024240216-A1 | PHARMACEUTICAL COMPOSITION FOR EFFECTIVELY DELAYING AND TREATING MYOPIA | 温州医科大学附属眼视光医院 | 2024-11-28 | — | — | WO | disclosed |
| CN-118634218-A | Pharmaceutical composition for effectively delaying and treating myopia | 温州医科大学附属眼视光医院 | 2024-09-13 | — | — | CN | disclosed |
| EP-4259152-B1 | CEMTIRESTAT DISULFIDE, PRODRUG OF ALDO-KETO REDUCTASE INHIBITOR, PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CENTRUM EXPERIMENTALNEJ MEDICINY SAV V V I (SK) | 2024-06-19 | — | — | EP | disclosed |
| CN-117757051-A | Preparation method and application of repeatable thermoplastic processing and controllable degradation photo-crosslinking polyester | 江南大学 | 2024-03-26 | — | — | CN | disclosed |
| EP-4259152-A1 | CEMTIRESTAT DISULFIDE, PRODRUG OF ALDO-KETO REDUCTASE INHIBITOR, PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Centrum Experimentálnej Medicíny Sav (SK) | 2023-10-18 | — | — | EP | disclosed |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2022132058-A1 | CEMTIRESTAT DISULFIDE, PRODRUG OF ALDO-KETO REDUCTASE INHIBITOR, PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CENTRUM EXPERIMENTÁLNEJ MEDICÍNY SAV (SK) | 2022-06-23 | — | — | WO | disclosed |
| US-11273145-B2 | Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor | SHAHID MUSLIM D (US) | 2022-03-15 | — | — | US | disclosed |
| CN-112807324-A | Cactus polysaccharide composition, blood pressure lowering medicine and health food | 郑仙兰 | 2021-05-18 | — | — | CN | disclosed |
| CN-112806502-A | Plant health-care beverage | 郑仙兰 | 2021-05-18 | — | — | CN | disclosed |
| US-20150238463-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR | SHAHID MUSLIM D (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150238463-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR | SHAHID MUSLIM D (US) | 2015-08-27 | — | — | US | disclosed |
| US-7184198-B2 | Display element | KONICA MINOLTA HOLDINGS, INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7184198-B2 | Display element | KONICA MINOLTA HOLDINGS, INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20040133938-A1 | Use of lipoic acid in plant culture media | MONSANTO TECHNOLOGY LLC | 2004-07-08 | — | — | US | disclosed |
| US-6313164-B1 | TO ENHANCE THE ACTIVITY OF GLUTATHIONE RECLUCTASE; FOR THERAPY AND PROPHYLAXIS OF CARTARACTS | SANKYO COMPANY, LIMITED (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1070710-A2 | Dithiolan derivatives, their preparation and their therapeutic effect | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-6013663-A | CATARACT THERAPY OR PREVENTION | SANKYO COMPANY, LIMITED (JP) | 2000-01-11 | — | — | US | disclosed |
| CN-1208035-A | Dithiolan derivatives, their preparation and their therapeutic effect | SANKYO CO (JP) | 1999-02-17 | — | — | CN | disclosed |
| EP-0869126-A1 | Dithiolan derivatives, their preparation and their therapeutic effect | Sankyo Company Limited (JP) | 1998-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273145-B2 | Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor | ALAD, FABP6, ALOX15B | HSD17B10 131/4885KMT2A 4570/4885TARDBP 2904/4885 |
| US-20040133938-A1 | Use of lipoic acid in plant culture media | TTPA, TST, LRAT | HSD17B10 762/4885KMT2A 1497/4885TARDBP 1949/4885 |
| US-20150238463-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR | FABP6, ALAD, SLC10A2 | HSD17B10 140/4885KMT2A 4550/4885TARDBP 2504/4885 |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SSB, UACA, CDA | HSD17B10 2163/4885KMT2A 199/4885TARDBP 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.